As of 2025-12-19, the EV/EBITDA ratio of Regenxbio Inc (RGNX) is -4.49. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. RGNX's latest enterprise value is 625.07 mil USD. RGNX's TTM EBITDA according to its financial statements is -139.16 mil USD. Dividing these 2 quantities gives us the above RGNX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 15.1x - 16.6x | 15.3x |
| Forward P/E multiples | 34.6x - 56.0x | 53.9x |
| Fair Price | (93.90) - (44.53) | (93.96) |
| Upside | -795.1% - -429.6% | -795.5% |
| Date | EV/EBITDA |
| 2025-12-18 | -4.49 |
| 2025-12-17 | -4.37 |
| 2025-12-16 | -4.71 |
| 2025-12-15 | -4.61 |
| 2025-12-12 | -4.62 |
| 2025-12-11 | -4.25 |
| 2025-12-10 | -4.33 |
| 2025-12-09 | -4.20 |
| 2025-12-08 | -4.39 |
| 2025-12-05 | -4.36 |
| 2025-12-04 | -4.30 |
| 2025-12-03 | -4.26 |
| 2025-12-02 | -4.02 |
| 2025-12-01 | -4.16 |
| 2025-11-28 | -4.45 |
| 2025-11-26 | -4.40 |
| 2025-11-25 | -4.47 |
| 2025-11-24 | -4.03 |
| 2025-11-21 | -3.87 |
| 2025-11-20 | -3.53 |
| 2025-11-19 | -3.55 |
| 2025-11-18 | -3.67 |
| 2025-11-17 | -3.63 |
| 2025-11-14 | -3.76 |
| 2025-11-13 | -3.81 |
| 2025-11-12 | -3.80 |
| 2025-11-11 | -3.78 |
| 2025-11-10 | -3.59 |
| 2025-11-07 | -3.66 |
| 2025-11-06 | -3.64 |
| 2025-11-05 | -3.80 |
| 2025-11-04 | -3.78 |
| 2025-11-03 | -3.94 |
| 2025-10-31 | -4.22 |
| 2025-10-30 | -4.24 |
| 2025-10-29 | -4.25 |
| 2025-10-28 | -4.36 |
| 2025-10-27 | -4.53 |
| 2025-10-24 | -4.32 |
| 2025-10-23 | -4.15 |
| 2025-10-22 | -4.01 |
| 2025-10-21 | -4.34 |
| 2025-10-20 | -4.18 |
| 2025-10-17 | -3.84 |
| 2025-10-16 | -4.07 |
| 2025-10-15 | -4.05 |
| 2025-10-14 | -3.67 |
| 2025-10-13 | -3.70 |
| 2025-10-10 | -3.55 |
| 2025-10-09 | -4.00 |